Skip to content
  • Sunday, 26 July 2026
  • 2:12 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Absci Secures $100 Million and Advances AI-Designed Drug Candidate ABS-201 for Endometriosis and Hair Loss
Pharmaceutical R&D

Absci Secures $100 Million and Advances AI-Designed Drug Candidate ABS-201 for Endometriosis and Hair Loss

Teuku Ryan Jun 28, 2026 0

Absci Corporation has successfully closed an underwritten public offering, raising approximately $100 million, a significant financial injection that will fuel…

Read More
Pharmaceutical R&D

Groundbreaking Diagnostic Innovations Promise to Halve Endometriosis Diagnosis Delays, Yet Systemic Hurdles Persist

Teuku Ryan Mar 31, 2026 0

Endometriosis, a debilitating chronic inflammatory condition affecting an estimated 10% of reproductive-age women globally, continues to be plagued by a…

Read More
Halozyme and Vertex sign deal for Hypercon technologyExploring the Cutting Edge: New eBook Dives into Single-Cell Spatial Omics, Cancer, Neurodevelopmental Diseases, and AI in Biomedical ResearchSolar Powered Plastic Transformation Offers Dual Solution to Global Pollution and Energy DemandsBiotech Bi-Weekly: Pioneering Product Launches, Strategic Alliances, and Significant Financial Movements Shape the Industry
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ